Header Logo

Connection

JOHN KIRKWOOD to Adjuvants, Immunologic

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Adjuvants, Immunologic.
JOHN KIRKWOOD
Connection Strength
4.123
Adjuvants, Immunologic
  1. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.642
  2. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
    View in: PubMed
    Score: 0.499
  3. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May; 35(4):359-66.
    View in: PubMed
    Score: 0.344
  4. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother. 2010 Jul-Aug; 33(6):630-8.
    View in: PubMed
    Score: 0.303
  5. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev. 2007 Oct-Dec; 18(5-6):451-8.
    View in: PubMed
    Score: 0.248
  6. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.224
  7. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
    View in: PubMed
    Score: 0.197
  8. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov; 29(11):2835-2843.
    View in: PubMed
    Score: 0.190
  9. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. Eur J Cancer. 2022 11; 176:207-217.
    View in: PubMed
    Score: 0.177
  10. An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
    View in: PubMed
    Score: 0.168
  11. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
    View in: PubMed
    Score: 0.153
  12. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 12 10; 36(35):3441-3449.
    View in: PubMed
    Score: 0.135
  13. Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother. 1997 May; 44(3):137-49.
    View in: PubMed
    Score: 0.122
  14. Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group. J Immunother. 1997 Mar; 20(2):146-57.
    View in: PubMed
    Score: 0.120
  15. Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
    View in: PubMed
    Score: 0.118
  16. IFN-a in the treatment of melanoma. J Immunol. 2012 Oct 15; 189(8):3789-93.
    View in: PubMed
    Score: 0.089
  17. Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci. 2009 Dec; 1182:47-57.
    View in: PubMed
    Score: 0.073
  18. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13; 12(3).
    View in: PubMed
    Score: 0.049
  19. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823.
    View in: PubMed
    Score: 0.046
  20. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022 11 10; 40(32):3741-3749.
    View in: PubMed
    Score: 0.043
  21. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
    View in: PubMed
    Score: 0.043
  22. Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653.
    View in: PubMed
    Score: 0.042
  23. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
    View in: PubMed
    Score: 0.042
  24. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther. 2000 Dec; 6(4):171-6.
    View in: PubMed
    Score: 0.039
  25. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008 Mar 01; 112(5):982-94.
    View in: PubMed
    Score: 0.016
  26. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery. 1982 Sep; 92(3):459-63.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.